Next Article in Journal
A Prospective Feasibility Trial to Challenge Patient–Derived Pancreatic Cancer Organoids in Predicting Treatment Response
Next Article in Special Issue
Hypnosis Sedation Reduces the Duration of Different Side Effects of Cancer Treatments in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Previous Article in Journal
Socio-Economic Deprivation and Symptom Burden in UK Hospice Patients with Advanced Cancer—Findings from a Longitudinal Study
Previous Article in Special Issue
A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Review

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment

1
Breast Cancer Unit, Hospital Universitario La Paz, 28046 Madrid, Spain
2
Gynaecology Department, Hospital Universitario La Paz, 28046 Madrid, Spain
3
IdiPaz—Instituto de Investigación La Paz, 28046 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Theodoros Foukakis
Cancers 2021, 13(11), 2538; https://doi.org/10.3390/cancers13112538
Received: 8 April 2021 / Revised: 16 May 2021 / Accepted: 19 May 2021 / Published: 21 May 2021
(This article belongs to the Special Issue Neoadjuvant Therapy in Breast Cancer)
The treatment of breast cancer has evolved considerably over the last two decades, leading toward individualized disease management. Hormone-sensitive breast cancers constitute the vast majority of cases and endocrine therapy is the mainstay of their treatment. On the other hand, neoadjuvant or pre-surgical treatments provide a number of advantages for tumor management. In this review we will discuss the existing evidence on neoadjuvant endocrine therapy, as well as its possible future indications.
Endocrine therapy (ET) has established itself as an efficacious treatment for estrogen receptor-positive (ER+) breast cancers, with a reduction in recurrence rates and increased survival rates. The pre-surgical approach with chemotherapy (NCT) has become a common form of management for large, locally advanced, or high-risk tumors. However, a good response to NCT is not usually expected in ER+ tumors. Good results with primary ET, mainly in elderly women, have encouraged studies in other stages of life, and nowadays neoadjuvant endocrine treatment (NET) has become a useful approach to many ER+ breast cancers. The aim of this review is to provide an update on the current state of art regarding the present and the future role of NET. View Full-Text
Keywords: breast cancer; endocrine therapy; neoadjuvant; resistance breast cancer; endocrine therapy; neoadjuvant; resistance
MDPI and ACS Style

Martí, C.; Sánchez-Méndez, J.I. The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment. Cancers 2021, 13, 2538. https://doi.org/10.3390/cancers13112538

AMA Style

Martí C, Sánchez-Méndez JI. The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment. Cancers. 2021; 13(11):2538. https://doi.org/10.3390/cancers13112538

Chicago/Turabian Style

Martí, Covadonga, and José I. Sánchez-Méndez 2021. "The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment" Cancers 13, no. 11: 2538. https://doi.org/10.3390/cancers13112538

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop